Exon-level TP53 alterations and PD-L1 expression identified by pretreatment NGS stratify survival in EGFR-mutant non-small cell lung cancer treated with first-line osimertinib
Mutations in <i>TP53</i> exon 5 are associated with a shorter first-line osimertinib treatment duration and OS. These findings might provide insight into a combination strategy for the first-line treatment of <i>EGFR</i> mutant NSCLC patients or a patient selection strategy for adjuvant osimertinib.
Authors
- D. Lee
- Ho‐Su Lee (ORCID: https://orcid.org/0000-0003-3711-2180)
- Kyung Noh Yoon (ORCID: https://orcid.org/0009-0001-2057-5907)
- Kang-Seo Park (ORCID: https://orcid.org/0000-0003-3005-3472)
- S. Kim
- Deokhoon Kim (ORCID: https://orcid.org/0000-0002-3597-1048)
- Hwang Hee-sang
- Bokyung Ahn
- Ji Eun Park
- Shinkyo Yoon
- Hwan Park
- Sang-We Kim
- Yongjae Kim
- Se Jin Jang
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/tlcr-2025-880
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00